10 Facts From the UK Government Pfizer Vaccine Guidance that Promote “Vaccine Hesitancy”.
No need for fake news.
Just look the official guidance for healthcare professionals to understand the dangers of the Covid vaccine.
@JohnnyVedmore explains.
1/11 https://unlimitedhangout.com/2020/12/reports/10-facts-from-the-uk-government-pfizer-vaccine-guidance-that-promote-vaccine-hesitancy/
No need for fake news.
Just look the official guidance for healthcare professionals to understand the dangers of the Covid vaccine.
@JohnnyVedmore explains.
1/11 https://unlimitedhangout.com/2020/12/reports/10-facts-from-the-uk-government-pfizer-vaccine-guidance-that-promote-vaccine-hesitancy/
This medicinal product does not have UK marketing authorisation but has been given authorisation only for temporary supply.
2/11
2/11
The official Phase III safety trials will not be completed until 2023.
3/11
3/11
Will you be truly “protected” from COVID-19?
4/11
4/11
The complicated multistage dilution and thawing process of the vaccine vials opens the major possibility of human error.
5/11
5/11
The safety and efficacy of COVID-19 mRNA Vaccine BNT162b2 in children under 16 years of age have not yet been established.
6/11
6/11
No data are available on the use of COVID-19 mRNA Vaccine BNT162b2 in persons that have previously received a full or partial vaccine series with another COVID-19 vaccine.
7/11
7/11
No interaction studies have been performed and there are no, or a limited amount of, data from the use of COVID-19 mRNA Vaccine BNT162b2.
8/11
8/11
It is unknown whether COVID-19 mRNA Vaccine BNT162b2 is excreted in human milk and It is unknown whether COVID-19 mRNA Vaccine BNT162b2 has an impact on fertility.
9/11
9/11
Non-clinical data reveal no special hazard for humans based on a conventional study of repeat dose toxicity but animal studies into potential toxicity to reproduction and development have not been completed.
10/11
10/11
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
11/11.
ENDS
11/11.
ENDS